Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomasz Zabinski

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Cancers|May 17, 2019
CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid MalignanciesLynsey M Whilding, Leena Halim, Benjamin Draper, et al.
Frontiers in Immunology|April 28, 2023
CD90 is not constitutively expressed in functional innate lymphoid cellsJan-Hendrik Schroeder, Gordon Beattie, Jonathan W Lo, et al.
Cell Reports|August 31, 2022
Organoids capture tissue-specific innate lymphoid cell development in mice and humansGeraldine M Jowett, Emily Read, Luke B Roberts, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 24, 2014
Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acidAna C Parente-Pereira, Hilary Shmeeda, Lynsey M Whilding, et al.
Frontiers in Immunology|November 19, 2021
Sustained Post-Developmental T-Bet Expression Is Critical for the Maintenance of Type One Innate Lymphoid Cells <i>In Vivo</i>Jan-Hendrik Schroeder, Luke B Roberts, Katrin Meissl, et al.
Oncoimmunology|December 7, 2017
CAR T-cell immunotherapy of MET-expressing malignant mesotheliomaThivyan Thayaparan, Roseanna M Petrovic, Daniela Y Achkova, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 4, 2026
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T CellsLynsey M Whilding, Ana C Parente-Pereira, Tomasz Zabinski, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 30, 2017
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T CellsLynsey M Whilding, Ana C Parente-Pereira, Tomasz Zabinski, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T CellsLynsey M Whilding, Ana C Parente-Pereira, Tomasz Zabinski, et al.
Nature Materials|September 8, 2020
ILC1 drive intestinal epithelial and matrix remodellingGeraldine M Jowett, Michael D A Norman, Tracy T L Yu, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cancers|May 17, 2019
CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid MalignanciesLynsey M Whilding, Leena Halim, Benjamin Draper, et al.
Frontiers in Immunology|April 28, 2023
CD90 is not constitutively expressed in functional innate lymphoid cellsJan-Hendrik Schroeder, Gordon Beattie, Jonathan W Lo, et al.
Cell Reports|August 31, 2022
Organoids capture tissue-specific innate lymphoid cell development in mice and humansGeraldine M Jowett, Emily Read, Luke B Roberts, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 24, 2014
Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acidAna C Parente-Pereira, Hilary Shmeeda, Lynsey M Whilding, et al.
Frontiers in Immunology|November 19, 2021
Sustained Post-Developmental T-Bet Expression Is Critical for the Maintenance of Type One Innate Lymphoid Cells <i>In Vivo</i>Jan-Hendrik Schroeder, Luke B Roberts, Katrin Meissl, et al.
Oncoimmunology|December 7, 2017
CAR T-cell immunotherapy of MET-expressing malignant mesotheliomaThivyan Thayaparan, Roseanna M Petrovic, Daniela Y Achkova, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 4, 2026
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T CellsLynsey M Whilding, Ana C Parente-Pereira, Tomasz Zabinski, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 30, 2017
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T CellsLynsey M Whilding, Ana C Parente-Pereira, Tomasz Zabinski, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T CellsLynsey M Whilding, Ana C Parente-Pereira, Tomasz Zabinski, et al.
Nature Materials|September 8, 2020
ILC1 drive intestinal epithelial and matrix remodellingGeraldine M Jowett, Michael D A Norman, Tracy T L Yu, et al.
Pageof 2